$NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Attack rates dropped 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. https://t.co/ljPC7Lww0D via @Jasonmmast
$NTLA HAE ph3 data on Monday.
@MichaelMaiello @YHdjdhd $NTLA offered the 30 calendar guidance, not the FDA.
$NTLA update on FDA clinical hold should be imminent, if not overdue already.
CRISPR-based treatment cuts cholesterol and triglycerides in early study https://t.co/Y03kJtJZYN via @matthewherper $CRSP $NTLA $LLY
$NTLA the Hy's Law patient died.
I don’t want $NTLA to go bankrupt. That would require spending all its cash. Wasteful. I said the company should return cash to shareholders. Big difference. One of the lessons of biotech’s disastrous multi year downturn is putting management teams and boards on shorter leashes. More accountability, less deference. Make hard decisions about capital allocation. Fail faster. Move on.
$NTLA FDA places ATTR-PN and CM trials on clinical hold. https://t.co/HE46BvvZUy
@robdubparker Save "blame the short seller" for tomorrow's $NTLA posting. You need to pace yourself.
We've reached the blame-the-patient stage in the $NTLA retail cult meltdown.
$BMRN tonight said it was divesting Roctavian, its underperforming gene therapy for hemophilia A. $NTLA take note. Time to wind down, return cash to shareholders. Salvage what you can.
@ZinselmeyerB @MichaelMaiello @_OliverVenture @GeneInvesting I disagree. The Hy's Law/DILI case absolutely impacts everyone because it changes the $NTLA risk/benefit equation. Will this trial even restart?
For Intellia $NTLA , CRISPR drug’s safety concern is an existential threat It is difficult to imagine a viable future for the biotech following pause in trials. Hy's Law, drug-induced liver injury. Intellia is done. https://t.co/pRLQq6AjWN
Hy’s Law is very very bad. $NTLA
Intellia $NTLA pauses two late-stage CRISPR gene-editing trials after emergence of safety concern -45% https://t.co/Bx2IeFUSE8 via @Jasonmmast
$NTLA For a company with a history of disclosure issues, this should be investigated. https://t.co/7JsEKvuPKR
$NTLA liver tox forces suspension of ATTR clinical trials https://t.co/0Lw7FPbNmD
@Sanctuary_Bio @A_May_MD @BlaseBio ARK Funds have been buying $NTLA recently, for instance.
